Kong Lin

Currently serving as Assistant to the President and Director of the Department of Head and Neck and Central Nervous System Oncology at Shanghai Proton and Heavy Ion Hospital. Principal Investigator of a Key Research and Development Program of the Ministry of Science and Technology, Chairman of the Proton and Heavy Ion Radiotherapy Committee of the China Association for the Promotion of Human Health Science and Technology, and Vice Chairman of the Particle Radiotherapy Committee of the Chinese Anti-Cancer Association. After graduating from university in 1993, he dedicated himself to radiotherapy for tumors, and received his Ph.D. in Oncology from Fudan University Shanghai Medical College in 2002. He is one of the earliest experts in China (starting in 2014) to systematically conduct proton and heavy ion radiotherapy for head and neck and neurological tumors. Internationally, he pioneered a prospective clinical study of taxane-based induction chemotherapy combined with conformal intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma, increasing the 5-year survival rate from 65% to 85%. He also pioneered the "adaptive fractionated irradiation" technique for chordoma treatment, achieving a local control rate exceeding 90%. In 2012, the first phase III randomized controlled trial was conducted internationally, investigating nimotuzumab as an alternative to cisplatin as a radiosensitizing agent for the treatment of locally advanced nasopharyngeal carcinoma. The research findings were invited to be presented at the ASCO and ASTRO annual meetings, making him one of the few Chinese experts to give an oral presentation at the ASCO annual meeting. He has received support from several key national projects, with research funding exceeding 10 million yuan.